Research ExplorerPublicationsIs further screening of men with baseline PSA 

Is further screening of men with baseline PSA 

Standard

Is further screening of men with baseline PSA  : The discussion continues-Results of the Swiss ERSPC (Aarau). / Randazzo, Marco; Beatrice, Josef; Huber, Andreas; Grobholz, Rainer; Manka, Lukas; Chun, Felix K; Kluth, Luis A; Wyler, Stephen F; Recker, Franz; Kwiatkowski, Maciej.

In: INT J CANCER, Vol. 137, No. 3, 01.08.2015, p. 553-9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Randazzo, M, Beatrice, J, Huber, A, Grobholz, R, Manka, L, Chun, FK, Kluth, LA, Wyler, SF, Recker, F & Kwiatkowski, M 2015, 'Is further screening of men with baseline PSA : The discussion continues-Results of the Swiss ERSPC (Aarau)', INT J CANCER, vol. 137, no. 3, pp. 553-9. https://doi.org/10.1002/ijc.29420

APA

Randazzo, M., Beatrice, J., Huber, A., Grobholz, R., Manka, L., Chun, F. K., Kluth, L. A., Wyler, S. F., Recker, F., & Kwiatkowski, M. (2015). Is further screening of men with baseline PSA : The discussion continues-Results of the Swiss ERSPC (Aarau). INT J CANCER, 137(3), 553-9. https://doi.org/10.1002/ijc.29420

Vancouver

Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK et al. Is further screening of men with baseline PSA : The discussion continues-Results of the Swiss ERSPC (Aarau). INT J CANCER. 2015 Aug 1;137(3):553-9. https://doi.org/10.1002/ijc.29420

Bibtex

@article{06eb17bbbaf2406d91c2b54917c98258,
title = "Is further screening of men with baseline PSA : The discussion continues-Results of the Swiss ERSPC (Aarau)",
abstract = "Recent studies indicate frequent early PSA retesting unrelated of men's baseline PSA, which increases the harms of early detection especially among men with low PSA. The current study investigates the PCa incidence among men with baseline PSA <1.0 ng ml(-1) in order to adjust retest intervals for more targeted early detection. Between 1998 and 2012, 2,416 men with baseline PSA <1.0 ng ml(-1) were prospectively observed. Primary endpoint was PCa diagnosis. Negative predictive value (NPV) and number needed to screen (NNS) to detect one PCa were calculated. During a median follow-up time of 12.1 years, 54 (2.2%) PCa were diagnosed with n = 26 (48.1%) among men with baseline PSA of 0.75 ≤ 1.0 ng ml(-1) (upper baseline PSA quartile). The 10-year probability of being diagnosed with PCa increased significantly from 0.19% (baseline PSA < 0.40 ng ml(-1) ) to 2.0% (baseline PSA 0.40 ≤ 0.56 ng ml(-1) ), 2.5% (baseline PSA 0.56 ≤ 0.75 ng ml(-1) ) over 4.4% (baseline PSA 0.75 ≤ 1.0 ng ml(-1) ) (all p values <0.0001), respectively. The frequency of Gleason ≥7 PCa increased from 1 (0.17%) to 8 (1.4%), 5 (0.8) over 11 (1.8%) in these groups. The 8-year NPV for Gleason ≥ 7 PCa were 99.8 (baseline PSA < 0.40 ng ml(-1) ), 99.8 (baseline PSA 0.40 ≤ 0.56 ng ml(-1) ), 100 (baseline PSA 0.56 ≤ 0.75 ng ml(-1) ) and 99.5 (baseline PSA 0.75 ≤ 1.0 ng ml(-1) ), respectively. During 12 years, the numbers were 99.8, 98.6, 99.2, and 98.2, respectively. Therefore, due to the very low rate of Gleason ≥ 7 PCa, further screening might be omitted in men with baseline PSA < 0.4 ng ml(-1) . Between 0.4 and 1.0 ng ml(-1) , an 8-year interval can be discussed.",
keywords = "Aged, Early Detection of Cancer, Follow-Up Studies, Humans, Incidence, Male, Mass Screening, Middle Aged, Neoplasm Grading, Prostate-Specific Antigen, Prostatic Neoplasms, Reference Values, Reproducibility of Results, Risk Factors, Switzerland, Journal Article, Research Support, Non-U.S. Gov't",
author = "Marco Randazzo and Josef Beatrice and Andreas Huber and Rainer Grobholz and Lukas Manka and Chun, {Felix K} and Kluth, {Luis A} and Wyler, {Stephen F} and Franz Recker and Maciej Kwiatkowski",
note = "{\textcopyright} 2015 UICC.",
year = "2015",
month = aug,
day = "1",
doi = "10.1002/ijc.29420",
language = "English",
volume = "137",
pages = "553--9",
journal = "INT J CANCER",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Is further screening of men with baseline PSA 

T2 - The discussion continues-Results of the Swiss ERSPC (Aarau)

AU - Randazzo, Marco

AU - Beatrice, Josef

AU - Huber, Andreas

AU - Grobholz, Rainer

AU - Manka, Lukas

AU - Chun, Felix K

AU - Kluth, Luis A

AU - Wyler, Stephen F

AU - Recker, Franz

AU - Kwiatkowski, Maciej

N1 - © 2015 UICC.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Recent studies indicate frequent early PSA retesting unrelated of men's baseline PSA, which increases the harms of early detection especially among men with low PSA. The current study investigates the PCa incidence among men with baseline PSA <1.0 ng ml(-1) in order to adjust retest intervals for more targeted early detection. Between 1998 and 2012, 2,416 men with baseline PSA <1.0 ng ml(-1) were prospectively observed. Primary endpoint was PCa diagnosis. Negative predictive value (NPV) and number needed to screen (NNS) to detect one PCa were calculated. During a median follow-up time of 12.1 years, 54 (2.2%) PCa were diagnosed with n = 26 (48.1%) among men with baseline PSA of 0.75 ≤ 1.0 ng ml(-1) (upper baseline PSA quartile). The 10-year probability of being diagnosed with PCa increased significantly from 0.19% (baseline PSA < 0.40 ng ml(-1) ) to 2.0% (baseline PSA 0.40 ≤ 0.56 ng ml(-1) ), 2.5% (baseline PSA 0.56 ≤ 0.75 ng ml(-1) ) over 4.4% (baseline PSA 0.75 ≤ 1.0 ng ml(-1) ) (all p values <0.0001), respectively. The frequency of Gleason ≥7 PCa increased from 1 (0.17%) to 8 (1.4%), 5 (0.8) over 11 (1.8%) in these groups. The 8-year NPV for Gleason ≥ 7 PCa were 99.8 (baseline PSA < 0.40 ng ml(-1) ), 99.8 (baseline PSA 0.40 ≤ 0.56 ng ml(-1) ), 100 (baseline PSA 0.56 ≤ 0.75 ng ml(-1) ) and 99.5 (baseline PSA 0.75 ≤ 1.0 ng ml(-1) ), respectively. During 12 years, the numbers were 99.8, 98.6, 99.2, and 98.2, respectively. Therefore, due to the very low rate of Gleason ≥ 7 PCa, further screening might be omitted in men with baseline PSA < 0.4 ng ml(-1) . Between 0.4 and 1.0 ng ml(-1) , an 8-year interval can be discussed.

AB - Recent studies indicate frequent early PSA retesting unrelated of men's baseline PSA, which increases the harms of early detection especially among men with low PSA. The current study investigates the PCa incidence among men with baseline PSA <1.0 ng ml(-1) in order to adjust retest intervals for more targeted early detection. Between 1998 and 2012, 2,416 men with baseline PSA <1.0 ng ml(-1) were prospectively observed. Primary endpoint was PCa diagnosis. Negative predictive value (NPV) and number needed to screen (NNS) to detect one PCa were calculated. During a median follow-up time of 12.1 years, 54 (2.2%) PCa were diagnosed with n = 26 (48.1%) among men with baseline PSA of 0.75 ≤ 1.0 ng ml(-1) (upper baseline PSA quartile). The 10-year probability of being diagnosed with PCa increased significantly from 0.19% (baseline PSA < 0.40 ng ml(-1) ) to 2.0% (baseline PSA 0.40 ≤ 0.56 ng ml(-1) ), 2.5% (baseline PSA 0.56 ≤ 0.75 ng ml(-1) ) over 4.4% (baseline PSA 0.75 ≤ 1.0 ng ml(-1) ) (all p values <0.0001), respectively. The frequency of Gleason ≥7 PCa increased from 1 (0.17%) to 8 (1.4%), 5 (0.8) over 11 (1.8%) in these groups. The 8-year NPV for Gleason ≥ 7 PCa were 99.8 (baseline PSA < 0.40 ng ml(-1) ), 99.8 (baseline PSA 0.40 ≤ 0.56 ng ml(-1) ), 100 (baseline PSA 0.56 ≤ 0.75 ng ml(-1) ) and 99.5 (baseline PSA 0.75 ≤ 1.0 ng ml(-1) ), respectively. During 12 years, the numbers were 99.8, 98.6, 99.2, and 98.2, respectively. Therefore, due to the very low rate of Gleason ≥ 7 PCa, further screening might be omitted in men with baseline PSA < 0.4 ng ml(-1) . Between 0.4 and 1.0 ng ml(-1) , an 8-year interval can be discussed.

KW - Aged

KW - Early Detection of Cancer

KW - Follow-Up Studies

KW - Humans

KW - Incidence

KW - Male

KW - Mass Screening

KW - Middle Aged

KW - Neoplasm Grading

KW - Prostate-Specific Antigen

KW - Prostatic Neoplasms

KW - Reference Values

KW - Reproducibility of Results

KW - Risk Factors

KW - Switzerland

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1002/ijc.29420

DO - 10.1002/ijc.29420

M3 - SCORING: Journal article

C2 - 25565393

VL - 137

SP - 553

EP - 559

JO - INT J CANCER

JF - INT J CANCER

SN - 0020-7136

IS - 3

ER -